title: Serotonergic anti-obesity agents: past experience and future prospects.
abstract: The role of serotonin (5-hydroxytryptamine) in appetite control is long established. Serotonergic manipulations reduce food intake in rodents in a manner consistent with satiety. In humans, drugs such as fenfluramine, dexfenfluramine and sibutramine all reduce energy intake, suppress hunger and enhance satiety. Effects on eating behaviour and subjective sensations of appetite are associated with the weight loss-inducing effects of these treatments. Currently, no appetite-suppressing drugs are approved specifically for the treatment of obesity. However, a new generation of serotonergic drugs have progressed through clinical development. The serotonin 5-HT(2C)-receptor selective agonist lorcaserin, a drug specifically developed to target satiety without producing the side effect profiles of its predecessors, has been shown to significantly reduce energy intake and body weight. The weight loss produced by lorcaserin appears modest, and behavioural effects, particularly its supposed satiety-enhancing effects, have yet to be characterized. The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies. It remains unclear if this drug produces any effects on appetite mediated by serotonin, or whether weight loss is produced largely through enhanced energy expenditure. Evidence indicates that tesofensine strengthens satiety, but behavioural specificity and psychological side effects remain an issue. The serotonergic system remains a viable target for anti-obesity treatment. In this review, we examine the limited behavioural data available on these two new CNS-acting appetite suppressants.
authors.affiliation: Experimental Psychology, University of Liverpool, Liverpool, UK. j.c.g.halford@liverpool.ac.uk
authors.forename: Jason C G
authors.initials: JC
authors.lastname: Halford
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Boyland
authors.forename: Clare L
authors.initials: CL
authors.lastname: Lawton
authors.forename: John E
authors.initials: JE
authors.lastname: Blundell
authors.forename: Joanne A
authors.initials: JA
authors.lastname: Harrold
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D058826:Serotonin 5-HT2 Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018490:Serotonin Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001552:Benzazepines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D058826:Serotonin 5-HT2 Receptor Agonists; D018490:Serotonin Agents; D017367:Selective Serotonin Reuptake Inhibitors; C506658:lorcaserin; C518479:Tesofensine
references.citation: Obes Res. 2004 Dec;12(12):2023-30
references.pmid: 15687404
references.citation: Int J Obes Relat Metab Disord. 1992 May;16(5):355-60
references.pmid: 1319970
references.citation: Arch Intern Med. 2004 May 10;164(9):994-1003
references.pmid: 15136309
references.citation: Psychopharmacology (Berl). 1997 Jun;131(3):264-70
references.pmid: 9203237
references.citation: Physiol Behav. 2001 Nov-Dec;74(4-5):507-16
references.pmid: 11790410
references.citation: Psychopharmacology (Berl). 1994 Sep;116(1):120-2
references.pmid: 7862925
references.citation: Int J Obes (Lond). 2010 Nov;34(11):1634-43
references.pmid: 20479765
references.citation: Appetite. 1988 Dec;11(3):215-28
references.pmid: 3250335
references.citation: Physiol Behav. 2005 Dec 15;86(5):614-22
references.pmid: 16225895
references.citation: Physiol Behav. 1996 Sep;60(3):933-9
references.pmid: 8873272
references.citation: Int J Obes Relat Metab Disord. 1995 May;19(5):299-304
references.pmid: 7647820
references.citation: Appetite. 1995 Aug;25(1):31-41
references.pmid: 7495325
references.citation: Pharmacol Biochem Behav. 1980 May;12(5):717-22
references.pmid: 7393965
references.citation: N Engl J Med. 2010 Jul 15;363(3):288-90
references.pmid: 20647205
references.citation: Br J Pharmacol. 1997 Aug;121(8):1613-8
references.pmid: 9283694
references.citation: Neuropsychopharmacology. 2010 Jun;35(7):1464-76
references.pmid: 20200509
references.citation: Psychopharmacology (Berl). 1994 Jan;113(3-4):369-77
references.pmid: 7862847
references.citation: N Engl J Med. 2010 Sep 2;363(10):905-17
references.pmid: 20818901
references.citation: Am J Clin Nutr. 2002 Mar;75(3):476-83
references.pmid: 11864852
references.citation: Obes Res. 1995 Mar;3(2):153-61
references.pmid: 7719961
references.citation: Int J Obes (Lond). 2007 Mar;31(3):435-9
references.pmid: 16953260
references.citation: J Psychopharmacol. 2010 Jan;24(1):99-109
references.pmid: 18755818
references.citation: Psychopharmacology (Berl). 1989;97(1):89-95
references.pmid: 2496433
references.citation: Obes Res. 1999 Jan;7(1):43-50
references.pmid: 10023729
references.citation: Br J Clin Psychol. 1988 Sep;27(3):269-70
references.pmid: 3191308
references.citation: Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16
references.pmid: 19777399
references.citation: J Am Diet Assoc. 1996 Jun;96(6):589-92; quiz 593-4
references.pmid: 8655907
references.citation: Int J Obes Relat Metab Disord. 2004 Dec;28(12):1548-54
references.pmid: 15543160
references.citation: Br J Pharmacol. 1991 Aug;103(4):2016-20
references.pmid: 1912990
references.citation: Neuropharmacology. 2001 Aug;41(2):200-9
references.pmid: 11489456
references.citation: Psychopharmacology (Berl). 1988;96(1):93-100
references.pmid: 2906446
references.citation: Expert Opin Investig Drugs. 2009 Jul;18(7):1043-6
references.pmid: 19548858
references.citation: Am J Clin Nutr. 1998 Dec;68(6):1180-6
references.pmid: 9846844
references.citation: Psychopharmacology (Berl). 2011 Apr;214(4):941-7
references.pmid: 21140257
references.citation: BMJ. 2008 Oct 21;337:a2002
references.pmid: 18940848
references.citation: Clin Pharmacol Ther. 2010 Jul;88(1):69-78
references.pmid: 20520602
references.citation: Obes Res. 2003 Jun;11(6):783-92
references.pmid: 12805400
references.citation: Appetite. 2007 Sep;49(2):399-404
references.pmid: 17391805
references.citation: Psychopharmacology (Berl). 1979 Nov;66(2):159-65
references.pmid: 119258
references.citation: Drugs. 2007;67(1):27-55
references.pmid: 17209663
references.citation: Psychopharmacology (Berl). 2002 Oct;164(1):49-60
references.pmid: 12373419
references.citation: Obes Res. 1998 Jan;6(1):1-11
references.pmid: 9526964
references.citation: Neuron. 2006 Jul 20;51(2):239-49
references.pmid: 16846858
references.citation: Physiol Behav. 2004 Jul;81(5):735-40
references.pmid: 15234178
references.citation: J Psychosom Res. 1972 Aug;16(4):305-8
references.pmid: 5080876
references.citation: Int J Obes. 1990 Apr;14(4):361-72
references.pmid: 2361813
references.citation: Physiol Behav. 2000 Jan;68(3):299-308
references.pmid: 10716539
references.citation: Int J Obes Relat Metab Disord. 2000 Dec;24(12):1715-25
references.pmid: 11126230
references.citation: J Clin Endocrinol Metab. 2011 Mar;96(3):837-45
references.pmid: 21190985
references.citation: Ann Med. 2000 Apr;32(3):222-32
references.pmid: 10821329
references.citation: Int J Obes Relat Metab Disord. 2004 Feb;28(2):262-8
references.pmid: 14647173
references.citation: Int J Obes (Lond). 2006 Jan;30(1):122-8
references.pmid: 16158086
references.citation: Lancet. 2008 Nov 29;372(9653):1906-1913
references.pmid: 18950853
references.citation: Brain Res Bull. 1990 Dec;25(6):953-60
references.pmid: 2149668
references.citation: Obesity (Silver Spring). 2009 Mar;17(3):494-503
references.pmid: 19057523
references.citation: Int J Obes Relat Metab Disord. 2002 Feb;26(2):262-73
references.pmid: 11850760
references.citation: Int J Obes. 1977;1(1):89-101
references.pmid: 617111
references.citation: Psychopharmacology (Berl). 2007 Apr;191(3):391-431
references.pmid: 17072591
references.citation: Nat Rev Endocrinol. 2010 Dec;6(12):663-4
references.pmid: 21102648
references.citation: Regul Pept. 2008 Aug 7;149(1-3):32-8
references.pmid: 18534696
references.citation: Proc Nutr Soc. 2007 May;66(2):277-85
references.pmid: 17466108
references.citation: Int J Obes. 1990 Mar;14(3):219-33
references.pmid: 2187822
references.citation: Nature. 1995 Apr 6;374(6522):542-6
references.pmid: 7700379
references.citation: Psychopharmacology (Berl). 1997 Oct;133(3):309-12
references.pmid: 9361339
references.citation: J Epidemiol. 2006 May;16(3):117-24
references.pmid: 16710080
references.citation: Diabetes. 2000 May;49(5):838-46
references.pmid: 10905495
references.citation: Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95
references.pmid: 20385125
references.citation: Diabetes. 2003 Feb;52(2):315-20
references.pmid: 12540602
references.citation: Ann N Y Acad Sci. 2003 Jun;994:169-74
references.pmid: 12851313
references.citation: Br J Pharmacol. 1988 May;94(1):137-47
references.pmid: 3401632
references.citation: Int J Obes. 1977;1(1):15-42
references.pmid: 361584
references.citation: Int J Obes. 1991 Mar;15(3):237-42
references.pmid: 1646182
references.citation: Int J Obes Relat Metab Disord. 2003 Dec;27(12):1437-46
references.pmid: 12975638
references.citation: Pharmacol Biochem Behav. 2002 Apr;71(4):691-700
references.pmid: 11888560
references.citation: Am J Clin Nutr. 2008 Dec;88(6):1560-6
references.pmid: 19064516
references.citation: Pharmacol Biochem Behav. 1996 Aug;54(4):745-51
references.pmid: 8853199
references.citation: Pharmacol Biochem Behav. 1998 Oct;61(2):159-68
references.pmid: 9738531
references.citation: N Engl J Med. 2010 Jul 15;363(3):245-56
references.pmid: 20647200
references.citation: Science. 2002 Jul 26;297(5581):609-11
references.pmid: 12142539
references.citation: Br J Pharmacol. 2008 Jan;153(1):164-74
references.pmid: 17982477
references.citation: N Engl J Med. 1996 Aug 29;335(9):609-16
references.pmid: 8692238
references.citation: Obes Res. 1995 Jul;3(4):345-56
references.pmid: 8521151